| This week's sponsor is Premier Research. | | | Clearing the Path for Orphan Drug Development
The unmet therapeutic need in rare disease is huge, but so are the cost and complexity of drug development. Read our white paper to see how the FDA and EMA are easing the path to regulatory approval. Premier Research. It's what we do. Best. |
Top Stories Friday, December 9, 2016 After dissecting its failed solanezumab failure at the CTAD meeting last night, Lilly is wasting no time moving on as it announces a new Alzheimer’s drug pact deal with partner AstraZeneca this morning. Friday, December 9, 2016 Leerink has delivered a rare vote of confidence in AstraZeneca and its beleaguered pipeline. Analysts at the investment bank named AstraZeneca as their top Big Pharma stock pick for 2017, citing a belief its pipeline prospects for next year and beyond are underappreciated to back up their decision. Thursday, December 8, 2016 Horizon Pharma’s Actimmune has missed the primary endpoint in a phase 3 trial, sparking a 20% drop in its stock price. The study set out to show interferon gamma-1b could improve outcomes in patients with the rare neurodegenerative movement disorder Friedreich's ataxia, but the drug failed to move the needle. Thursday, December 8, 2016 Since it launched its Watson Health unit last spring, IBM has rolled out cognitive computing tools for a number of applications, including genomics and oncology. But while the Jeopardy-winning supercomputer has generated a lot of buzz, critics are still wondering: is Watson really useful in these areas? Thursday, December 8, 2016 Prosecutors have worked their way to the top of Insys Therapeutics. After arresting a series of lower-level workers, the Justice Department on Thursday hauled in former CEO Michael Babich and a group of other execs. Thursday, December 8, 2016 In this week's EuroBiotech Report, uniQure’s ASH fizzles, EMA accepts Sanofi drug for review, TiGenix tees up IPO and more. Friday, December 9, 2016 In this week's FiercePharmaAsia wrap-up, Takeda and VC Lightstone have joined forces in forming a neuroscience startup, China's cancer research is narrowing the U.S. lead, Sun's Halol plant was hit by FDA notice again, and more. Thursday, December 8, 2016 FDA’s John Jenkins retires after 15 years leading the OND, Teva’s generics CEO Olafsson exits with Actavis’ transition still on the agenda, and Deborah Waterhouse will replace Dominique Limet as ViiV Healthcare's CEO. Plus more hirings, firings and retirings throughout the industry. | | | Alzheon says new data from its late-stage test shows the "largest clinical effects of tramiprosate in APOE4/4 patients with mild Alzheimer’s." Release Novartis' latest data for its oncology candidate ribociclib, alongside letrozole, shows superior survival rates in some patients with first-line HR+/HER2- advanced breast cancer, against using letrozole alone. Statement Biohaven' BHV-0223 has been handed an orphan drug tag for patients with amyotrophic lateral sclerosis. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. CBI’s IISR 2017 Summit February 14-15, 2017 | Philadelphia, PA FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Precision LBx Summit: Translating Next Generation Liquid Biopsies into Clinical Reality January 30-February 1, 2017 | San Diego, CA DeviceTalks December 12, 2016 | Newport Beach, CA | 